Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of the concept of students learning practical gynecological and obstetric skills at a large German university hospital, using the example of the Homburg university women's clinic.

Archives of gynecology and obstetrics·2026

Same author

Clinicopathological Characteristics and Treatment Patterns of Extremity, Trunk, and Axial Sarcomas: A Descriptive Real-World Cohort Study from a Romanian Tertiary Oncology Center.

Diagnostics (Basel, Switzerland)·2026

Same author

Approaches to Intraepithelial Cervical Neoplasia Management in Pregnancy: A Narrative Review.

Life (Basel, Switzerland)·2026

Same author

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.

Journal of medical Internet research·2026

Same author

Multi-Protein Profiling Reveals High Nuclear KFL-4 Expression as a Predictor of Poor Overall Survival in Breast Cancer: A Retrospective Cohort Study.

International journal of molecular sciences·2026

Same author

PROMs: Patient related or patient centred? A bridge between Patient-Reported Outcome Measures (PROMs) and clinical ethics in the context of a cohort of gynaeco-oncological patients analysed by qualitative semi- structured interviews.

Journal of patient-reported outcomes·2026

Same journal

Correction to "Radiotherapy and Cardiovascular Disease Survival Risk in Non-Small Cell Lung Cancer: A Population-Based Study From the Surveillance, Epidemiology, and End Results Database".

Cancer medicine·2026

Same journal

Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.

Cancer medicine·2026

Same journal

Years of Life Lost of Patients With Early Adenocarcinoma of the Esophagogastric Junction Compared to Esophageal or Gastric Adenocarcinoma. A Registry-Based Study.

Cancer medicine·2026

Same journal

Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

Cancer medicine·2026

Same journal

Cholesterol-Lowering Treatment Blocks Epithelial-Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models.

Cancer medicine·2026

Same journal

Factors Associated With Optimal Patient-Clinician Communication Among Cancer Survivors.

Cancer medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Intravital Microscopy of the Inguinal Lymph Node

Intravital Microscopy of the Inguinal Lymph Node

Published on: April 4, 2011

ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study.

Meletios P Nigdelis¹, Annick Bitterlich², Mariam Parvanta²

¹Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), Homburg, Germany.

Cancer Medicine

|August 23, 2025

Summary

This summary is machine-generated.

ROS1 expression in vulvar squamous cell carcinoma (VSCC) is linked to lymph node involvement but not overall survival. Further research is needed to explore ROS1 as a therapeutic target for VSCC.

Keywords:

ROS1 immunohistochemistry tyrosine kinase inhibitors vulvar cancer

More Related Videos

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Published on: October 20, 2010

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Published on: March 8, 2013

Related Experiment Videos

Last Updated: Sep 10, 2025

Intravital Microscopy of the Inguinal Lymph Node

Intravital Microscopy of the Inguinal Lymph Node

Published on: April 4, 2011

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Published on: October 20, 2010

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Published on: March 8, 2013

Area of Science:

Oncology
Pathology
Molecular Biology

Background:

Systemic treatment options for vulvar squamous cell carcinoma (VSCC) are limited.
ROS1, a tyrosine kinase, shows promise as a therapeutic target in other cancers like non-small cell lung cancer (NSCLC).

Purpose of the Study:

To investigate immunohistochemical ROS1 expression in VSCC.
To explore the potential of ROS1 as a future therapeutic target in VSCC.

Main Methods:

Retrospective study of 48 VSCC patients.
Immunohistochemistry (IHC) to assess ROS1 expression (0-3 scale).
Logistic regression and survival models to analyze ROS1 association with lymph node involvement and overall survival.

Main Results:

ROS1 expression was significantly associated with inguinal lymph node involvement (OR 2.396, p=0.042).
No significant difference in overall survival was observed between ROS1-positive and ROS1-negative VSCC tumors (HR 0.837, p=0.738).

Conclusions:

ROS1 expression correlates with lymph node metastasis in VSCC.
ROS1 is not currently associated with overall survival in VSCC patients.
Further investigation is warranted to clarify ROS1's role in VSCC therapeutics.